一堂課讓你認識肺癌(Basic Concepts of Lung Cancer: Diagnosis and Treatment)

Start Date: 01/24/2021

Course Type: Common Course

Course Link: https://www.coursera.org/learn/lung-cancer

About Course

本課程共有四周,介紹肺的功能、肺癌形成的原因、以及肺癌的分期與治療,完成課程後將對肺癌有初步的認識。 根據衛生福利部統計,民國105年台灣死於肺癌的人數高達9372人,這其中有許多是不吸煙,也沒有家族病史的病患,這些病患對本身如何得到肺癌往往得不到答案。但抬頭看看我們的天空,不論是大陸吹來的沙塵暴,或是我們台灣本島製造的空污,早已將天空蒙上一層灰,因此空污對於肺癌,實在有著密不可分的關聯。其實對於肺癌,有個早期篩檢的利器—低劑量電腦斷層篩檢,這項篩檢無需禁食,也不用打顯影劑,只要五分鐘左右即可完成,只可惜因為需要自費,因此許多人望之卻步,也讓許多人失去了早期篩檢出肺癌的機會。希望藉由這門課可以讓大家對台灣新國病—肺癌有不同的認識,也希望大家能更重視呼吸的健康。

Coursera Plus banner featuring three learners and university partner logos

Course Introduction

本課程共有四周,介紹肺的功能、肺癌形成的原因、以及肺癌的分期與治療,完成課程後將對肺癌有初步的認識。 根據衛生福利部統計,民國105年台灣死於肺癌的人數高達9372人,這其中有許多是不吸煙,也沒有家

Course Tag

Related Wiki Topic

Article Example
Treatment of lung cancer There are typically three objectives applied to the treatment of lung cancer and can vary by patient or individual diagnosis: (1) curing lung cancer, (2) controlling lung cancer, and (3) being comfortable.
Clinical Lung Cancer "Clinical Lung Cancer" publishes articles on detection, diagnosis, prevention, and treatment of lung cancer. The emphasis is on recent scientific developments in all areas related to lung cancer.
Treatment of lung cancer Lung cancer is an extremely heterogeneous family of malignant neoplasms, and well over 50 different histopathological variants are currently recognized under the most widely used typing system. Because these variants have differing genetic, biological, and clinical properties, including response to treatment, correct classification of lung cancer cases are necessary to assure that lung cancer patients receive optimum management.
Treatment of lung cancer Squalamine is undergoing trials for treatment of non-small cell lung cancer (stage I/IIA).
Treatment of lung cancer In patients with stage 3 lung cancer that cannot be removed, treatment with combined radiotherapy and chemotherapy improves survival significantly.
Treatment of lung cancer Approximately 98% of lung cancers are carcinoma, or tumors derived from transformed cells of epithelial lineage. Currently, nearly four dozen different histopathological variants of lung carcinoma are recognized. For clinical and treatment purposes, however, most oncologists tend to classify lung carcinomas into two major groups, namely small cell carcinoma (SCLC) and non-small cell lung cancer (NSCLC). This is done because of differing responses to treatment — NSCLC is comparatively less sensitive to chemotherapy and/or radiation, so surgery is the treatment of choice in these tumors. SCLC, in contrast, usually initially responds well to chemotherapy and/or radiation, but has usually metastasized widely by the time it is discovered, making surgery ineffective.
Lung cancer Lung cancer staging is an assessment of the degree of spread of the cancer from its original source. It is one of the factors affecting the prognosis and potential treatment of lung cancer.
Treatment of lung cancer Treatment of lung cancer refers to the use of medical therapies, such as surgery, radiation, chemotherapy, percutaneous ablation, and palliative care, alone or in combination, in an attempt to cure or lessen the adverse impact of malignant neoplasms originating in lung tissue.
Treatment of lung cancer Erlotinib (Tarceva), another EGFR tyrosine kinase inhibitor, increased survival in non-small cell lung cancer and was approved by the FDA in 2004 for second-line treatment of advanced non-small cell lung carcinoma. Similar to gefitinib, it also appeared to work best in females, Asians, nonsmokers, and those with bronchioloalveolar carcinoma, particularly those with specific mutations in EGFR.
Lung cancer Worldwide in 2012, lung cancer occurred in 1.8 million people and resulted in 1.6 million deaths. This makes it the most common cause of cancer-related death in men and second most common in women after breast cancer. The most common age at diagnosis is 70 years. Overall, 17.4% of people in the United States diagnosed with lung cancer survive five years after the diagnosis, while outcomes on average are worse in the developing world.
Timeline of lung cancer This is a timeline of lung cancer, describing especially major discoveries, advances in treatment and major organizations.
Treatment of lung cancer Prior to the early part of the 20th century lung cancer was considered a very rare disease, and all malignant lung tumors were treated identically. Radical surgical resection (i.e. lobectomy or pneumonectomy) was the only effective intervention available for lung cancer prior to the 1940s, when the era of modern cytotoxic chemotherapy began.
Lung cancer Lung cancer often appears as a solitary pulmonary nodule on a chest radiograph. However, the differential diagnosis is wide. Many other diseases can also give this appearance, including metastatic cancer, hamartomas, and infectious granulomas such as tuberculosis, histoplasmosis and coccidioidomycosis. Lung cancer can also be an incidental finding, as a solitary pulmonary nodule on a chest radiograph or CT scan done for an unrelated reason. The definitive diagnosis of lung cancer is based on histological examination of the suspicious tissue in the context of the clinical and radiological features.
Cancer research Cancer research is basic research into cancer to identify causes and develop strategies for prevention, diagnosis, treatment, and cure.
Lung cancer Treatment for lung cancer depends on the cancer's specific cell type, how far it has spread, and the person's performance status. Common treatments include palliative care, surgery, chemotherapy, and radiation therapy. Targeted therapy of lung cancer is growing in importance for advanced lung cancer.
Treatment of lung cancer In recent years, various molecular targeted therapies have been developed for the treatment of advanced lung cancer. Gefitinib (Iressa; withdrawn from the U.S. market) is one such drug, which targets the tyrosine kinase domain of the epidermal growth factor receptor (EGFR), expressed in many cases of non-small cell lung carcinoma. It was not shown to increase survival, although females, Asians, nonsmokers, and those with bronchioloalveolar carcinoma appear to derive the most benefit from gefitinib.
Lung cancer staging This section focuses on the emerging role various types of endoscopic ultrasound and biopsy are playing in the diagnosis and staging of lung cancer, with an emphasis on the most common type of lung cancer, non-small cell lung cancer (NSCLC). These techniques have been reviewed extensively and have attained substantial consensus in guidelines such as from the NCCN.
Lung cancer staging The diagnosis of lung cancer is based on chest radiograph and computer tomography (CT) scans, and is confirmed by biopsy. Biopsy is usually performed via bronchoscopy or CT-guided biopsy. Treatment and prognosis depend upon the histological type of cancer, the stage, and the patient's performance status. Treatments include surgery, chemotherapy, and radiotherapy.
Lung cancer staging In medicine, lung cancer staging is the assessment of the extent to which a lung cancer has spread from its original source. As with most cancers, staging is an important determinant of treatment and prognosis. In general, more advanced stages of cancer are less amenable to treatment and have a worse prognosis.
Lung cancer Asbestos can cause a variety of lung diseases, including lung cancer. Tobacco smoking and asbestos have a synergistic effect on the formation of lung cancer. In smokers who work with asbestos, the risk of lung cancer is increased 45-fold compared to the general population. Asbestos can also cause cancer of the pleura, called mesothelioma (which is different from lung cancer).